Hodgkin's lymphoma in younger patients: lessons learned on the road to success.
Despite significant improvements in the treatment of Hodgkin's lymphoma over the past 2 decades, physicians continue to face dilemmas in therapy for the disease, and many cured patients live with complications of treatment. Newer therapeutic options are still needed for the disease, to minimize complications and to improve the treatment of patients in relapse. This review considers the treatment of Hodgkin's lymphoma in younger patients, addressing such issues as which patients with early-stage disease may require radiotherapy, what prognostic factors provide information that can affect treatment choices in patients with advanced disease, and what we have learned about treatment complications in this setting.
Hagemeister
Fredrick B
FB
Department of Hematology, The University of Texas M.D. Anderson Cancer Center Houston, Texas 77030, USA. fhagemei@.mdanderson.org
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D017741:Survivors